Imatinib and beyond - Exploring the full potential of targeted therapy for CML

Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will require alternative therapy at some point owing to safety reasons or lack of efficacy. Achieving an early response with imatinib is protective against treatment failure; second-generation tyrosine kinase inhibitors (TKIs; for example, nilotinib, dasatinib, bosutinib), however, have proven to be efficacious at restoring cytogenetic responses in patients who require subsequent therapy. Response duration, however, is yet to be established and a considerable proportion of patients fail to achieve a clinically meaningful response. A third generation of TKIs is currently undergoing clinical testing for use in patients who fail imatinib and a second-generation TKI. Most of these agents are multikinase inhibitors with activity against a wide variety of BCR-ABL1 mutations, including the highly resistant T315I. The use of second-generation TKIs in the frontline setting seems to provide higher rates of early response compared with imatinib. If these results are confirmed in randomized studies, nilotinib and dasatinib could replace imatinib as standard frontline therapy in CML. Despite the activity of all of the above mentioned agents, curing CML will ultimately depend on the development of agents capable of vanquishing BCR-ABL1-positive CML stem cells. Efforts aimed at achieving this goal are ongoing.

Original languageEnglish (US)
Pages (from-to)535-543
Number of pages9
JournalNature Reviews Clinical Oncology
Volume6
Issue number9
DOIs
StatePublished - Nov 26 2009
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Myeloid Progenitor Cells
Therapeutics
Complementary Therapies
Treatment Failure
Cytogenetics
Protein-Tyrosine Kinases
Imatinib Mesylate
Safety
Mutation
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Dasatinib

ASJC Scopus subject areas

  • Oncology

Cite this

Imatinib and beyond - Exploring the full potential of targeted therapy for CML. / Quintás-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge.

In: Nature Reviews Clinical Oncology, Vol. 6, No. 9, 26.11.2009, p. 535-543.

Research output: Contribution to journalReview article

Quintás-Cardama, Alfonso ; Kantarjian, Hagop ; Cortes, Jorge. / Imatinib and beyond - Exploring the full potential of targeted therapy for CML. In: Nature Reviews Clinical Oncology. 2009 ; Vol. 6, No. 9. pp. 535-543.
@article{8cefd8d80187499e9794f755b5e73f4b,
title = "Imatinib and beyond - Exploring the full potential of targeted therapy for CML",
abstract = "A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will require alternative therapy at some point owing to safety reasons or lack of efficacy. Achieving an early response with imatinib is protective against treatment failure; second-generation tyrosine kinase inhibitors (TKIs; for example, nilotinib, dasatinib, bosutinib), however, have proven to be efficacious at restoring cytogenetic responses in patients who require subsequent therapy. Response duration, however, is yet to be established and a considerable proportion of patients fail to achieve a clinically meaningful response. A third generation of TKIs is currently undergoing clinical testing for use in patients who fail imatinib and a second-generation TKI. Most of these agents are multikinase inhibitors with activity against a wide variety of BCR-ABL1 mutations, including the highly resistant T315I. The use of second-generation TKIs in the frontline setting seems to provide higher rates of early response compared with imatinib. If these results are confirmed in randomized studies, nilotinib and dasatinib could replace imatinib as standard frontline therapy in CML. Despite the activity of all of the above mentioned agents, curing CML will ultimately depend on the development of agents capable of vanquishing BCR-ABL1-positive CML stem cells. Efforts aimed at achieving this goal are ongoing.",
author = "Alfonso Quint{\'a}s-Cardama and Hagop Kantarjian and Jorge Cortes",
year = "2009",
month = "11",
day = "26",
doi = "10.1038/nrclinonc.2009.112",
language = "English (US)",
volume = "6",
pages = "535--543",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Imatinib and beyond - Exploring the full potential of targeted therapy for CML

AU - Quintás-Cardama, Alfonso

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2009/11/26

Y1 - 2009/11/26

N2 - A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will require alternative therapy at some point owing to safety reasons or lack of efficacy. Achieving an early response with imatinib is protective against treatment failure; second-generation tyrosine kinase inhibitors (TKIs; for example, nilotinib, dasatinib, bosutinib), however, have proven to be efficacious at restoring cytogenetic responses in patients who require subsequent therapy. Response duration, however, is yet to be established and a considerable proportion of patients fail to achieve a clinically meaningful response. A third generation of TKIs is currently undergoing clinical testing for use in patients who fail imatinib and a second-generation TKI. Most of these agents are multikinase inhibitors with activity against a wide variety of BCR-ABL1 mutations, including the highly resistant T315I. The use of second-generation TKIs in the frontline setting seems to provide higher rates of early response compared with imatinib. If these results are confirmed in randomized studies, nilotinib and dasatinib could replace imatinib as standard frontline therapy in CML. Despite the activity of all of the above mentioned agents, curing CML will ultimately depend on the development of agents capable of vanquishing BCR-ABL1-positive CML stem cells. Efforts aimed at achieving this goal are ongoing.

AB - A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will require alternative therapy at some point owing to safety reasons or lack of efficacy. Achieving an early response with imatinib is protective against treatment failure; second-generation tyrosine kinase inhibitors (TKIs; for example, nilotinib, dasatinib, bosutinib), however, have proven to be efficacious at restoring cytogenetic responses in patients who require subsequent therapy. Response duration, however, is yet to be established and a considerable proportion of patients fail to achieve a clinically meaningful response. A third generation of TKIs is currently undergoing clinical testing for use in patients who fail imatinib and a second-generation TKI. Most of these agents are multikinase inhibitors with activity against a wide variety of BCR-ABL1 mutations, including the highly resistant T315I. The use of second-generation TKIs in the frontline setting seems to provide higher rates of early response compared with imatinib. If these results are confirmed in randomized studies, nilotinib and dasatinib could replace imatinib as standard frontline therapy in CML. Despite the activity of all of the above mentioned agents, curing CML will ultimately depend on the development of agents capable of vanquishing BCR-ABL1-positive CML stem cells. Efforts aimed at achieving this goal are ongoing.

UR - http://www.scopus.com/inward/record.url?scp=70450193142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450193142&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2009.112

DO - 10.1038/nrclinonc.2009.112

M3 - Review article

C2 - 19652654

AN - SCOPUS:70450193142

VL - 6

SP - 535

EP - 543

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 9

ER -